Jubilant Pharmova posts 14% FY26 revenue growth to Rs. 8,280 crore amid margin pressure
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
The hospital chain reported strong growth driven by its Gurugram facility, international patient inflow, and operational efficiencies
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
Subscribe To Our Newsletter & Stay Updated